期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

β_(3-)肾上腺素受体激动剂类减肥药的研究进展 被引量：2

Progress of Research and Development of β_(3-)Adrenoceptor Agonists as Antiobesity Drugs
下载PDF
导出
摘要 β3-肾上腺素受体可调节人体热量平衡、葡萄糖代谢、能量消耗并纠正产热不足,可用于治疗肥胖症和2型糖尿病。选择性b3-肾上腺素受体激动剂主要有芳基乙醇胺和芳氧基丙醇胺两类,本文对这些化合物的研究进展进行了综述。 The b3-adrenoceptor plays a role in energy balance and glucose homeostasis. b3-Adrenoceptor agonisthas promising potential to be a therapeutic agent in the treatment of obesity and type 2 diabetes. Selective b3-adrenoceptoragonists fall into two main chemical classes, arylethanolamines and aryloxypropanolamines. This review is focused on theprogress of research and development of these compounds as antiobesity drugs.
作者 尹健 陈再新 张奕华
机构地区 中国药科大学新药研究中心 江苏亚邦药物研发有限公司
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2005年第3期180-184,共5页 Chinese Journal of Pharmaceuticals
关键词 β3-肾上腺素受体 激动剂 减肥药 综述 β_3-adrenoceptor agonist antiobesity drug review
分类号 R979.9 [医药卫生—药品]
  • 相关文献

参考文献33

  • 1Weyer C, De Souza CJ. Development of β3-adrenoceptor agonists as antiobesity and antidiabetes drugs in humans:current status and future prospects [J]. Drug Dev Res, 2000,51 (2) : 80-93.
  • 2Emorine LJ, Marullo S, Briend-Sutren MM, et al. Molecular charaterisation of the human β3-adrenergic receptor[J].Science, 1989, 241 (4922) : 1118-1121.
  • 3Smith SA, Levy AL, Sennitt MV, et al. Effects of BRL 26830,a novel β-adrenoceptor agonist, on glucose tolerance, insulin sensitivity and glucose turnover in Zucker (fa/fa) rats [J].Biochem Pharmacol, 1985, 34 (14) : 2425-2429.
  • 4Gong DW, He YF, Karas M, Reitman M, et al. Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, β3-adrenergic agonists, and leptin [J]. J Biol Chem,1997. 272 (39) :24129-24132.
  • 5Arch JRS, Ainsworth AT, Cawthome MA, et al. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs [J]. Nature, 1984, 309 (5964) : 163-165.
  • 6Connacher AA, Bennet WM, Jung RT, et al. Metabolic effects of three weeks administration of the β-adrenoceptor agonist BRL 26830A [J]. lnt J Obes, 1992, 16 (9): 685-694.
  • 7Anonymous. BRL-35135A [J]. Drugs Future, 1996, 21 (9) :947-948.
  • 8Naylor EM, Colandrea VJ, Candelore MR, et al. 3-Pyridyl-ethanolamines: potent and selective human β3 adrenergic receptor agonists [J]. Bioorg Med Chem Left, 1998, 8 (21):3087-3092.
  • 9Sher PM, Mathur A, Fisher LG, et al. Carboxyl-promoted enhancement of selectivity for the β3 adrenergic receptor.Negative charge of the sulfonic acid BMS- 187413 introduces β3 binding, seletivity [J]. Bioorg Med Chem Lett, 1997, 7 (12) :1583-1588.
  • 10Langston S. Monitor: molecules and profiles [J]. Drug Disc Today, 2002, 7 (4) : 268-269.

同被引文献19

  • 1黄桢.肾上腺素能β_3受体激动剂[J].国外医药（合成药．生化药．制剂分册）,1995,16(2):67-73. 被引量：1
  • 2刘昭前,孙红,刘亚利,周宏灏.特异性β3肾上腺素能受体激动剂研究进展[J].中国药理学通报,2005,21(10):1153-1157. 被引量：8
  • 3陈光勇,陈旭冰,刘才平,刘光明,邓杰.α-溴-4-苄氧基苯乙酮的合成[J].大理学院学报（综合版）,2007,6(2):8-9. 被引量：3
  • 4Naylor EM;Colandrea GH;Macintyre DE.3-pyridyletholamines:potent and selective human beta3 adrenergic receptor agonists[J],1998.
  • 5Gavai AV;Sher PM;Mikkilineni AB.BMS196085:apotent and selective full agonist of the humanβ3 adrenergic receptor[J],2001(23).
  • 6Washburn WN;Sher PM;Poss KM.β3 agonists.Part 1:Evolution from inception to BMS-194449[J],2001(23).
  • 7Weyer C;Tataranni PA;Snitker S.Increase in insulin action and fat oxidation after treatment with CL-2316243,a highly selective beta 3-adrenceptor agonist in humans[J],1998(10).
  • 8Naylor EM;Colandrea VJ;Candelore MR.3-Pyridylethanolamines:potent and selective human β3 adrenergicreceptor agonists[J],1998(21).
  • 9Anonymous.BRL-35135A,1996(09).
  • 10Connacher AA;Bennet WM;Jung RT.Metabolic effects of three weeks administration of the β-adrenoceptor agonist BRL 26830A,1992(09).

引证文献2

二级引证文献2

中国医药工业杂志
2005年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部